Publication | Open Access
Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study
46
Citations
21
References
2017
Year
In this prospective phase II study, pazopanib demonstrated promising activity and tolerable safety profile in patients with metastatic nccRCC.
| Year | Citations | |
|---|---|---|
Page 1
Page 1